With Added Indication, Amarin Says Vascepa No ‘Fish Oil’ Like Omega-3s
Executive Summary
In Amarin’s “education process” about indication as an add-on to statin therapy to help cut CV risk in high-risk patients, it “will also be emphasizing how Vascepa is different from” Rx drugs fenofibrate and niacin “and omega-3 mixtures,” says CEO John Thero.
You may also be interested in...
Statin Drug Makes SPORT Of Supplements In Pharma-Funded, 28-Day Trial On Lowering LDL
Primary and secondary endpoint results in “Supplements, Placebo, or Rosuvastatin” study conducted by Cleveland Clinic include no difference, after four weeks, in total cholesterol and blood triglyceride measures between subjects receiving placebo and those using fish oil, cinnamon, garlic, turmeric, plant sterols or red yeast rice.
Solving US Hemp Regulatory Problem Will Take Wider View Of FDA Rule – AHPA’s McGuffin
FDA, along with supplement and food industries, have looked to Congress to authorizing agency to waive exclusion rule for hemp ingredients. Instead, Michael McGuffin recommends amending DSHEA to clarify that the same ingredients at different concentrations can be allowed in supplements and drugs.
US Omega-3 Supplement Firm Changes Claims On Amarin Challenge, But Not Label Or Company Name
National Advertising Division, in rare review of an Rx drug firm’s challenge of supplement ad claims, reported Innovix Pharma pulled health claims for OmegaVia brand supplements challenged by Amarin. Innovix prevailed in defending its labeling as accurate and its name as not false advertising.